All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The MM-003 trial compared pomalidomide treatment on a background of either low- or high- dose dexamethasone (POM+LoDEX or POM+HiDEX), for the treatment of relapsed and refractory Multiple Myeloma (RRMM) patients, that did not respond to their last line of treatment. The success of POM+LoDEX in this trial saw pomalidomide licensed for use in patients that have received at least two prior regimens, including lenalidomide and bortezomib. In a Letter to the Editor of Haematologica (the Journal for the European Hematology Association, EHA) K.W. Song and colleagues report an extended analysis of the MM-003 trial, in which they assessed health-related quality of life (HrQoL) and showed a significant benefit for the POM+LoDEX regimen. The design of the MM-003 trial is described in a previous MMHub article.
Following the success of the MM-003 clinical trial and improved clinical outcome with POM+LoDEX, this has become the standard of care treatment for relapsing patients who have previously received lenalidomide and bortezomib. This study concludes that POM+LoDEX leads to significant HRQoL improvements over time, often compromised in this patient set at this stage of their treatment journey, but an important factor nonetheless.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox